Cyclophosphamide promotes engraftment of gene-modified cells in a mouse model of Fanconi anemia without causing cytogenetic abnormalities

Jennifer E. Adair, Xin Zhao, Sylvia Chien, Min Fang, Martin E. Wohlfahrt, Grant D. Trobridge, Jason Taylor, Brian C. Beard, Hans Peter Kiem, Pamela S. Becker

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

A major hurdle for hematopoietic stem cell (HSC) gene therapy for inherited bone marrow disorders, including Fanconi anemia (FA), is adequate engraftment of gene-modified cells. A phenotypic defect in DNA repair renders FA patients sensitive to alkylating agents such as cyclophosphamide (Cy); however, at lower doses, Cy is well tolerated in the FA transplant setting. We tested whether non-alkylating agents could replace Cy for pretransplant conditioning to enhance engraftment of FANCA gene-modified hematopoietic cells. We compared Cy preconditioning with fludarabine (Flu) or cytarabine (AraC) or no conditioning as a control in fanca -/- mutant mice receiving gene-modified bone marrow cells. Only mice conditioned with Cy exhibited appreciable engraftment of gene-modified cells by PCR and resistance to mitomycin C (MMC). Cy administration following transplantation increased gene marking levels in all animals treated, but highest gene marking and corresponding MMC resistance were observed in mice receiving Cy pre- and posttransplantation. Importantly, no cytogenetic abnormalities were observed in Cy-treated mice. We conclude that Cy is an effective and superior preparative regimen with respect to engraftment of lentivirus-transduced cells and functional correction in fanca -/- mice. Thus, appropriately dosed Cy may provide a suitable conditioning regimen for FA patients undergoing HSC gene therapy.

Original languageEnglish (US)
Pages (from-to)1283-1294
Number of pages12
JournalJournal of Molecular Medicine
Volume90
Issue number11
DOIs
StatePublished - Nov 2012

Fingerprint

Fanconi Anemia
Chromosome Aberrations
Cyclophosphamide
Genes
Mitomycin
Cell- and Tissue-Based Therapy
Hematopoietic Stem Cells
Genetic Therapy
Lentivirus
Alkylating Agents
Cytarabine
DNA Repair
Bone Marrow Cells
Transplantation
Bone Marrow
Transplants

Keywords

  • Autologous transplantation
  • Cyclophosphamide
  • Fanconi anemia
  • Gene therapy
  • Lentivirus vector

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery
  • Genetics(clinical)

Cite this

Cyclophosphamide promotes engraftment of gene-modified cells in a mouse model of Fanconi anemia without causing cytogenetic abnormalities. / Adair, Jennifer E.; Zhao, Xin; Chien, Sylvia; Fang, Min; Wohlfahrt, Martin E.; Trobridge, Grant D.; Taylor, Jason; Beard, Brian C.; Kiem, Hans Peter; Becker, Pamela S.

In: Journal of Molecular Medicine, Vol. 90, No. 11, 11.2012, p. 1283-1294.

Research output: Contribution to journalArticle

Adair, JE, Zhao, X, Chien, S, Fang, M, Wohlfahrt, ME, Trobridge, GD, Taylor, J, Beard, BC, Kiem, HP & Becker, PS 2012, 'Cyclophosphamide promotes engraftment of gene-modified cells in a mouse model of Fanconi anemia without causing cytogenetic abnormalities', Journal of Molecular Medicine, vol. 90, no. 11, pp. 1283-1294. https://doi.org/10.1007/s00109-012-0905-0
Adair, Jennifer E. ; Zhao, Xin ; Chien, Sylvia ; Fang, Min ; Wohlfahrt, Martin E. ; Trobridge, Grant D. ; Taylor, Jason ; Beard, Brian C. ; Kiem, Hans Peter ; Becker, Pamela S. / Cyclophosphamide promotes engraftment of gene-modified cells in a mouse model of Fanconi anemia without causing cytogenetic abnormalities. In: Journal of Molecular Medicine. 2012 ; Vol. 90, No. 11. pp. 1283-1294.
@article{e5df51a08229479aaf28584e6c59587c,
title = "Cyclophosphamide promotes engraftment of gene-modified cells in a mouse model of Fanconi anemia without causing cytogenetic abnormalities",
abstract = "A major hurdle for hematopoietic stem cell (HSC) gene therapy for inherited bone marrow disorders, including Fanconi anemia (FA), is adequate engraftment of gene-modified cells. A phenotypic defect in DNA repair renders FA patients sensitive to alkylating agents such as cyclophosphamide (Cy); however, at lower doses, Cy is well tolerated in the FA transplant setting. We tested whether non-alkylating agents could replace Cy for pretransplant conditioning to enhance engraftment of FANCA gene-modified hematopoietic cells. We compared Cy preconditioning with fludarabine (Flu) or cytarabine (AraC) or no conditioning as a control in fanca -/- mutant mice receiving gene-modified bone marrow cells. Only mice conditioned with Cy exhibited appreciable engraftment of gene-modified cells by PCR and resistance to mitomycin C (MMC). Cy administration following transplantation increased gene marking levels in all animals treated, but highest gene marking and corresponding MMC resistance were observed in mice receiving Cy pre- and posttransplantation. Importantly, no cytogenetic abnormalities were observed in Cy-treated mice. We conclude that Cy is an effective and superior preparative regimen with respect to engraftment of lentivirus-transduced cells and functional correction in fanca -/- mice. Thus, appropriately dosed Cy may provide a suitable conditioning regimen for FA patients undergoing HSC gene therapy.",
keywords = "Autologous transplantation, Cyclophosphamide, Fanconi anemia, Gene therapy, Lentivirus vector",
author = "Adair, {Jennifer E.} and Xin Zhao and Sylvia Chien and Min Fang and Wohlfahrt, {Martin E.} and Trobridge, {Grant D.} and Jason Taylor and Beard, {Brian C.} and Kiem, {Hans Peter} and Becker, {Pamela S.}",
year = "2012",
month = "11",
doi = "10.1007/s00109-012-0905-0",
language = "English (US)",
volume = "90",
pages = "1283--1294",
journal = "Journal of Molecular Medicine",
issn = "0946-2716",
publisher = "Springer Verlag",
number = "11",

}

TY - JOUR

T1 - Cyclophosphamide promotes engraftment of gene-modified cells in a mouse model of Fanconi anemia without causing cytogenetic abnormalities

AU - Adair, Jennifer E.

AU - Zhao, Xin

AU - Chien, Sylvia

AU - Fang, Min

AU - Wohlfahrt, Martin E.

AU - Trobridge, Grant D.

AU - Taylor, Jason

AU - Beard, Brian C.

AU - Kiem, Hans Peter

AU - Becker, Pamela S.

PY - 2012/11

Y1 - 2012/11

N2 - A major hurdle for hematopoietic stem cell (HSC) gene therapy for inherited bone marrow disorders, including Fanconi anemia (FA), is adequate engraftment of gene-modified cells. A phenotypic defect in DNA repair renders FA patients sensitive to alkylating agents such as cyclophosphamide (Cy); however, at lower doses, Cy is well tolerated in the FA transplant setting. We tested whether non-alkylating agents could replace Cy for pretransplant conditioning to enhance engraftment of FANCA gene-modified hematopoietic cells. We compared Cy preconditioning with fludarabine (Flu) or cytarabine (AraC) or no conditioning as a control in fanca -/- mutant mice receiving gene-modified bone marrow cells. Only mice conditioned with Cy exhibited appreciable engraftment of gene-modified cells by PCR and resistance to mitomycin C (MMC). Cy administration following transplantation increased gene marking levels in all animals treated, but highest gene marking and corresponding MMC resistance were observed in mice receiving Cy pre- and posttransplantation. Importantly, no cytogenetic abnormalities were observed in Cy-treated mice. We conclude that Cy is an effective and superior preparative regimen with respect to engraftment of lentivirus-transduced cells and functional correction in fanca -/- mice. Thus, appropriately dosed Cy may provide a suitable conditioning regimen for FA patients undergoing HSC gene therapy.

AB - A major hurdle for hematopoietic stem cell (HSC) gene therapy for inherited bone marrow disorders, including Fanconi anemia (FA), is adequate engraftment of gene-modified cells. A phenotypic defect in DNA repair renders FA patients sensitive to alkylating agents such as cyclophosphamide (Cy); however, at lower doses, Cy is well tolerated in the FA transplant setting. We tested whether non-alkylating agents could replace Cy for pretransplant conditioning to enhance engraftment of FANCA gene-modified hematopoietic cells. We compared Cy preconditioning with fludarabine (Flu) or cytarabine (AraC) or no conditioning as a control in fanca -/- mutant mice receiving gene-modified bone marrow cells. Only mice conditioned with Cy exhibited appreciable engraftment of gene-modified cells by PCR and resistance to mitomycin C (MMC). Cy administration following transplantation increased gene marking levels in all animals treated, but highest gene marking and corresponding MMC resistance were observed in mice receiving Cy pre- and posttransplantation. Importantly, no cytogenetic abnormalities were observed in Cy-treated mice. We conclude that Cy is an effective and superior preparative regimen with respect to engraftment of lentivirus-transduced cells and functional correction in fanca -/- mice. Thus, appropriately dosed Cy may provide a suitable conditioning regimen for FA patients undergoing HSC gene therapy.

KW - Autologous transplantation

KW - Cyclophosphamide

KW - Fanconi anemia

KW - Gene therapy

KW - Lentivirus vector

UR - http://www.scopus.com/inward/record.url?scp=84868145166&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868145166&partnerID=8YFLogxK

U2 - 10.1007/s00109-012-0905-0

DO - 10.1007/s00109-012-0905-0

M3 - Article

C2 - 22660274

AN - SCOPUS:84868145166

VL - 90

SP - 1283

EP - 1294

JO - Journal of Molecular Medicine

JF - Journal of Molecular Medicine

SN - 0946-2716

IS - 11

ER -